Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).

ABSTRACT:

Purpose

The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known.

Materials and methods

We queried the U.S. Food and Drug Administration Adverse Event Reporting System, a retrospective, pharmacovigilance database, for cardiovascular adverse event reports in men with prostate cancer receiving gonadotropin releasing hormone (GnRH) agonists, GnRH antagonists, androgen receptor antagonists, and/or androgen synthesis inhibitors from January 2000 to April 2020.

Results

Cardiovascular adverse events accounted for 6,231 reports (12.6%) on hormone monotherapy and 1,793 reports (26.1%) on combination therapy. Arterial vascular events were reported most commonly, followed by arrhythmias, heart failure, and veno

SUBMITTER: Zhang KW 

PROVIDER: S-EPMC10243352 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature